{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:55Z","timestamp":1786991215957,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jaapos.2015.09.006","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T17:00:44Z","timestamp":1449939644000},"page":"541-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term follow-up of intravitreal bevacizumab\u00a0for\u00a0the treatment of pediatric retinal\u00a0and choroidal diseases"],"prefix":"10.1016","volume":"19","author":[{"given":"Christopher R.","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Tzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audina M.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2015.09.006_bib1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3928\/15428877-20100830-03","article-title":"Bevacizumab for the treatment of pediatric retinal and choroidal diseases","volume":"41","author":"Sisk","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jaapos.2015.09.006_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/IIO.0b013e318200df83","article-title":"Anti-vascular endothelial growth factor agents for pediatric retinal diseases","volume":"51","author":"Wykoff","year":"2011","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jaapos.2015.09.006_bib3","first-page":"574","article-title":"Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model","volume":"145","author":"Miller","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(98)93020-2","article-title":"Vascular endothelial growth factor upregulation in human central retinal vein occlusion","volume":"105","author":"Pe\u2019er","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2015.09.006_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0161-6420(00)00663-1","article-title":"Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction","volume":"108","author":"Lip","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2015.09.006_bib6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am J\u00a0Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3928\/01913913-20120821-02","article-title":"An evidence-based review\u00a0of vascular endothelial growth factor inhibition in pediatric retinal diseases: Part 2. Coats\u2019 disease, Best disease, and uveitis with childhood neovascularization","volume":"50","author":"Chaudhary","year":"2013","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2015.09.006_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaapos.2015.09.006_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3928\/01913913-20090903-10","article-title":"Treatment of choroidal neovascularization associated with Best\u2019s disease in children","volume":"46","author":"Rich","year":"2009","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2015.09.006_bib11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00417-012-2180-8","article-title":"Long term follow-up after single intravitreal ranibizumab injection for choroidal neovascularization secondary to optic nerve head drusen in a 5-year old child","volume":"251","author":"Baillif","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007446","article-title":"Paediatric choroidal osteoma treated with ranibizumab","author":"Vayalambrone","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaapos.2015.09.006_bib13","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archopht.126.8.1152","article-title":"Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy","volume":"126","author":"Benevento","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib14","first-page":"314","article-title":"Intravitreal bevacizumab for posttraumatic choroidal neovascularization in a child","volume":"15","author":"Piermarocchi","year":"2011","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2015.09.006_bib15","first-page":"48","article-title":"Peripapillary choroidal neovascular membrane in a teenage boy: presenting feature of idiopathic intracranial hypertension and resolution with intravitreal bevacizumab","volume":"33","author":"Belliveau","year":"2013","journal-title":"J\u00a0Neuro-Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib16","first-page":"616","article-title":"Ranibizumab for coloboma-related choroidal neovascular membrane in a child","volume":"13","author":"Goodwin","year":"2009","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2015.09.006_bib17","first-page":"288","article-title":"Intravitreal bevacizumab in choroidal neovascularization associated with congenital choroidal and optic nerve coloboma in children: long-term improvement in visual acuity","volume":"14","author":"Naithani","year":"2010","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2015.09.006_bib18","first-page":"296","article-title":"Intravitreal bevacizumab for idiopathic choroidal neovascularization","volume":"13","author":"Cakir","year":"2009","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2015.09.006_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3129\/i10-123","article-title":"Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series","volume":"46","author":"Kohly","year":"2011","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00417-010-1366-1","article-title":"Elevated vascular endothelial growth factor level in Coats\u2019 disease and possible therapeutic role of bevacizumab","volume":"248","author":"He","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/IAE.0b013e3181c2e0b7","article-title":"The effect of intravitreal bevacizumab in the treatment of coats disease in children","volume":"30","author":"Lin","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00417-013-2409-1","article-title":"The effect of intravitreal bevacizumab injection as the initial treatment for Coats\u2019 disease","volume":"252","author":"Zheng","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/bjophthalmol-2012-302250","article-title":"Treatment of Coats\u2019 disease with intravitreal bevacizumab","volume":"97","author":"Ray","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/IAE.0b013e318203c01e","article-title":"Letter to the editor","volume":"31","author":"Wells","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjophthalmol-2011-300141","article-title":"Bevacizumab for Coats\u2019 disease with exudative retinal detachment and risk of vitreoretinal traction","volume":"96","author":"Ramasubramanian","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib26","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00417-008-0949-6","article-title":"Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab","volume":"246","author":"Tagami","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.sjopt.2011.01.012","article-title":"Intravitreal bevacizumab for pediatric exudative retinal diseases","volume":"25","author":"Salman","year":"2011","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib28","first-page":"336","article-title":"Iris neovascularization and neovascular glaucoma in neurofibromatosis type 1: report of 3 cases in children","volume":"22","author":"Freihi","year":"2013","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.jaapos.2015.09.006_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ajo.2009.03.023","article-title":"Long-term visual\u00a0outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization","volume":"148","author":"Mansour","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib30","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/eye.2008.388","article-title":"Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular edema with intraocular bevacizumab","volume":"23","author":"Weiss","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.jaapos.2015.09.006_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1755-3768.2009.01662.x","article-title":"Vasoproliferative retinal tumours in a Swedish population","volume":"89","author":"Makidoumi","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.jaapos.2015.09.006_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ajo.2009.06.010","article-title":"Bevacizumab in inflammatory eye disease","volume":"148","author":"Lott","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0161-6420(98)96002-X","article-title":"Familial exudative vitreoretinopathy: results\u00a0of surgical management","volume":"105","author":"Pendergast","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2015.09.006_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bjo.2007.124586","article-title":"Choroidal neovascularization in children","volume":"92","author":"Sivaprasad","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3928\/0191-3913-19880101-07","article-title":"Choroidal neovascularization in children: report of five cases and literature review","volume":"25","author":"Wilson","year":"1988","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2015.09.006_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3928\/0191-3913-19950501-11","article-title":"Subretinal neovascularization in children and adolescents","volume":"32","author":"Goshorn","year":"1995","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2015.09.006_bib37","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00006982-200507000-00009","article-title":"Photodynamic therapy for choroidal neovascularization in pediatric patients","volume":"25","author":"Giansanti","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0161-6420(99)00510-2","article-title":"Surgical management of subfoveal neovascular membranes in children","volume":"106","author":"Sears","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2015.09.006_bib39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archopht.118.10.1373","article-title":"Visual outcomes after surgical removal of choroidal neovascularization in children","volume":"118","author":"Uemura","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib40","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1097\/IAE.0000000000000200","article-title":"Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents","volume":"34","author":"Kozak","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0002-9394(01)00896-0","article-title":"Classification and management of Coats disease: the 2000 Proctor Lecture","volume":"131","author":"Shields","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib42","first-page":"973","article-title":"Advanced Coats\u2019 disease treated with intravitreal bevacizumab combined with laser vascular ablation","volume":"8","author":"Villegas","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib43","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/IAE.0b013e3181679bf6","article-title":"Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib\u00a0sodium (Macugen)","volume":"28","author":"Quiram","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2015.09.006_bib46","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","article-title":"Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity","volume":"115","author":"Sonmez","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2015.09.006_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/IAE.0b013e318195cb15","article-title":"Concentration of cytokines in the aqueous humor of patients with na\u00efve, recurrent, and regressed cnv associated with amd after bevacizumab treatment","volume":"29","author":"Roh","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/IAE.0b013e3181b9f153","article-title":"Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion","volume":"30","author":"Park","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2015.09.006_bib49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3928\/01913913-20120821-03","article-title":"An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: Part 1. Retinopathy of prematurity","volume":"49","author":"Mititelu","year":"2012","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2015.09.006_bib50","first-page":"329","article-title":"Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern","volume":"13","author":"Avery","year":"2009","journal-title":"J\u00a0AAPOS"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853115005819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853115005819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:20:51Z","timestamp":1761078051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853115005819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1091853115005819"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2015.09.006","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up of intravitreal bevacizumab\u00a0for\u00a0the treatment of pediatric retinal\u00a0and choroidal diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2015.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}